Research programme: osteoarthritis therapeutics - Quark/Shionogi
Latest Information Update: 02 Sep 2010
At a glance
- Originator Quark Biotech; Shionogi
- Developer Quark Pharmaceuticals; Shionogi
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Osteoarthritis
Most Recent Events
- 24 Feb 2009 Early research is ongoing the US & Japan
- 31 Jan 2000 Early research in Osteoarthritis in Japan (Unknown route)
- 31 Jan 2000 Early research in Osteoarthritis in USA (Unknown route)